Design and rationale of the COMPARE-TAVI 2 trial: An all-comers head-to-head comparison of Evolut FX+ and Sapien 3 Ultra Resilia transcatheter heart valves
The COMPARE-TAVI 2 will provide important information on the short- and long-term outcomes among patients treated with the Evolut FX+ self-expandable and the Sapien 3 Ultra Resilia balloon-expandable THVs.
Authors
- Henrik Vase
- Henrik Dahl Nissen (ORCID: https://orcid.org/0000-0002-5002-5463)
- Mikko Jalanko (ORCID: https://orcid.org/0000-0001-5409-3300)
- Pertti Jääskeläinen
- Rebekka Vibjerg Jensen (ORCID: https://orcid.org/0000-0001-6539-5275)
- Matti Niemelä (ORCID: https://orcid.org/0000-0001-6671-5023)
- Ashkan Eftekhari
- Henrik Toft Sørensen
- Christian Alcaraz Frederiksen
- Christian Juhl Terkelsen
- Lars Pedersen
- Mikko Savontaus
- Mark Hensey
- Bjarne Linde Nørgaard
- Evald Høj Christiansen
Institutions
- Oulu University Hospital (FI)
- Aalborg University Hospital (DK)
- Helsinki University Hospital (FI)
- Odense University Hospital (DK)
- Turku University Hospital (FI)
- Aarhus University Hospital (DK)
- Kuopio University Hospital (FI)
- St. James's Hospital (IE)
Publication Details
- Journal
- American Heart Journal
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1016/j.ahj.2026.107387
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00